This video has been sponsored by AstraZeneca. The views and opinions expressed are those of the speakers and not necessarily those of AstraZeneca, or EMJ.
Join host Brigitte Scott and Ketta Lorusso, a leading expert in gynaecological malignancies, for an in-depth video interview exploring the crucial advancements in endometrial cancer research in 2024.
Key Topics Covered:
- Progression-free and overall survival benefits.
- Impact of mismatch repair (MMR) status (dMMR and pMMR).
- The role of chemotherapy–immunotherapy combinations with or without PARP inhibitors.
- Quality of life improvements.
- Evolving standards of care.
- Updated ESGO guidelines.
For further information, a Year in Review Article supported by a medical education grant from AstraZeneca in an EMJ Oncology supplement can be found here
Speaker
Prof. Ketta Lorusso1
1. Professor of Obstetrics and Gynaecology at Humanitas University of Milan, Italy
